Overview
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a synthetic 83-amino-acid analog of native IGF-1. It incorporates two modifications: an Arg3 substitution at position 3 (replacing Glu3) and a 13-amino-acid N-terminal extension peptide. These changes reduce its affinity for IGF-binding proteins (IGFBPs) by approximately 1000-fold, resulting in a half-life of 20–30 hours compared to the 12–15 hour half-life of native IGF-1. IGF-1 LR3 is used extensively in biopharmaceutical cell culture applications as a media supplement to promote cell growth and viability — this is its primary legitimate commercial application. It is also studied in animal models for anabolic, metabolic, and neuroprotective effects.
Mechanism
IGF-1 LR3 activates the IGF-1 receptor (IGF-1R), a tyrosine kinase receptor that initiates the PI3K/Akt and MAPK/ERK signaling cascades. These pathways promote protein synthesis, inhibit apoptosis, stimulate glucose uptake, and mediate cellular proliferation and differentiation. The reduced IGFBP binding means a greater fraction remains in the free (bioactive) form compared to native IGF-1, amplifying receptor activation per unit dose.
Research Areas
Side Effects (Preclinical)
- – Hypoglycemia (IGF-1 receptors are expressed in insulin-responsive tissues)
- – Organ enlargement with chronic supraphysiological dosing in animal studies
- – Potential mitogenic effects at high doses
Cautions
- – For research use only — not approved for human use
- – Significant hypoglycemia risk; IGF-1 is more potent than insulin at activating insulin receptor
- – Proliferative effects raise theoretical cancer-promotion concerns in relevant research contexts
- – Not the same compound as pharmaceutical Increlex (mecasermin; native IGF-1)
What the research shows
IGF-1 LR3’s primary validated application is as a biopharmaceutical cell culture media supplement — it is widely used in GMP manufacturing of biologic drugs, which gives it a well-characterized safety and stability profile in vitro. Its research use in animal models for anabolic effects is more controversial and less rigorously studied than the GH secretagogue compounds above it in this category.
The hypoglycemia risk from IGF-1 class compounds is real and significant — researchers working with IGF-1 LR3 in animal models routinely monitor blood glucose. This risk profile makes it higher-caution than most other peptides in this library.
References
- Pharmacokinetics and pharmacodynamics of long R3 IGF-I in healthy adults — Guler HP et al. (1998)
- IGF-1 and its receptor signaling pathways in health and disease — Laron Z. (2001)